Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.
Updates in the Treatment of HR+ Breast Cancer
Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.
A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.
A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.
A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.
A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.
A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.
A panel of experts discuss navigating 2L treatment strategies.
A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.
A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.
A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.
A panel of experts offer future perspectives in HR+ breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5